Scarica l'app Stockscreener
2.35
5.62%
-0.14
Dopo l'orario di chiusura:
2.33
-0.02
-0.85%
Precedente Chiudi:
$2.49
Aprire:
$2.5
Volume 24 ore:
482.53K
Relative Volume:
0.92
Capitalizzazione di mercato:
$132.25M
Reddito:
$76.19M
Utile/perdita netta:
$-1.61M
Rapporto P/E:
235.00
EPS:
0.01
Flusso di cassa netto:
$28.98M
1 W Prestazione:
-0.42%
1M Prestazione:
+23.68%
6M Prestazione:
+217.57%
1 anno Prestazione:
+89.52%
Intervallo 1D:
$2.34
$2.52
Intervallo di 1 settimana:
$2.24
$2.52
Portata 52W:
$0.5052
$3.22
Spero Therapeutics Inc Stock (SPRO) Company Profile
Nome
Spero Therapeutics Inc
Settore
Industria
Telefono
857-242-1600
Indirizzo
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Confronta SPRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.35 | 132.81M | 76.19M | -1.61M | 28.98M | 0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-20 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-23 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-10-01 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-01-22 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-16 | Iniziato | Berenberg | Buy |
| 2020-09-29 | Iniziato | Evercore ISI | Outperform |
| 2019-11-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-09-09 | Iniziato | Janney | Buy |
| 2018-02-09 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-11-27 | Iniziato | BofA/Merrill | Neutral |
| 2017-11-27 | Iniziato | Oppenheimer | Outperform |
| 2017-11-27 | Iniziato | Stifel | Buy |
Mostra tutto
Spero Therapeutics Inc Borsa (SPRO) Ultime notizie
Spero Therapeutics (NASDAQ:SPRO) Cut to Hold at Zacks Research - Defense World
Forecasting Spero Therapeutics Inc. price range with options data2025 Institutional Moves & AI Powered Market Trend Analysis - newser.com
What drives Spero Therapeutics Inc stock priceGap Fill Strategies & Free Unlock Portfolio Growth - earlytimes.in
Spero Therapeutics Inc Stock Analysis and ForecastSector Rotation Strategies & Free Superior Stock Performance - earlytimes.in
What MACD signals say about Spero Therapeutics Inc.Portfolio Performance Summary & Weekly Watchlist of Top Performers - newser.com
Reversal indicators forming on Spero Therapeutics Inc. stockPortfolio Return Summary & Weekly High Return Stock Opportunities - newser.com
What does recent volatility data suggest for Spero Therapeutics Inc.2025 Investor Takeaways & Stock Portfolio Risk Management - newser.com
How strong is Spero Therapeutics Inc. stock revenue growth2025 Breakouts & Breakdowns & Verified Momentum Stock Alerts - newser.com
Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek - GlobeNewswire
Phase 3 PIVOT-PO: Spero Therapeutics to present oral tebipenem HBr cUTI data at IDWeek Oct 20 - Stock Titan
Is Spero Therapeutics Inc a good long term investmentTechnology Stock Trends & Free Stock Index Interpretations - earlytimes.in
Is Spero Therapeutics Inc. (2HA) stock positioned for digital growth eraMarket Risk Analysis & Weekly High Potential Stock Alerts - newser.com
Key resistance and support levels for Spero Therapeutics Inc.Portfolio Gains Report & Stock Timing and Entry Methods - newser.com
Sector ETF performance correlation with Spero Therapeutics Inc.July 2025 Reactions & Consistent Income Trade Recommendations - newser.com
Best Momentum Stock to Buy for October 10th - Yahoo Finance
Spero Therapeutics' (SPRO) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
What analysts say about Spero Therapeutics Inc stockSell Signals and Alerts & Breakthrough Investment Results - earlytimes.in
Spero Therapeutics (NASDAQ:SPRO) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
October 2025's Promising Penny Stocks To Consider - simplywall.st
Key metrics from Spero Therapeutics Inc.’s quarterly dataWall Street Watch & Low Risk High Reward Ideas - newser.com
Heatmap analysis for Spero Therapeutics Inc. and competitors2025 Institutional Moves & Weekly Breakout Watchlists - newser.com
Is Spero Therapeutics Inc. (2HA) stock safe for risk averse investors2025 Short Interest & Risk Adjusted Swing Trade Ideas - newser.com
Spero Therapeutics, Inc. (NASDAQ:SPRO) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Will Spero Therapeutics Inc. see short term momentumTrade Analysis Report & Daily Volume Surge Signals - newser.com
Spero Therapeutics CEO sells shares worth $121,159 - MSN
Spero Therapeutics Inc. stock trend forecastJuly 2025 Levels & Real-Time Chart Breakout Alerts - newser.com
Spero Therapeutics Inc Azioni (SPRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Spero Therapeutics Inc Azioni (SPRO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Keutzer Timothy | Chief Operating Officer |
Aug 28 '25 |
Sale |
1.97 |
1,695 |
3,339 |
739,744 |
| Keutzer Timothy | Chief Operating Officer |
Feb 05 '25 |
Sale |
0.78 |
56,537 |
44,099 |
741,439 |
| Rajavelu Esther | CFO & CBO |
Feb 05 '25 |
Sale |
0.78 |
20,689 |
16,137 |
724,720 |
| Shukla Sath | CEO & President |
Feb 05 '25 |
Sale |
0.78 |
155,333 |
121,160 |
1,736,883 |
| Mahadevia Ankit | Director |
Feb 05 '25 |
Sale |
0.78 |
69,219 |
53,991 |
689,866 |
| Rajavelu Esther | CFO & CBO |
Nov 07 '24 |
Sale |
1.31 |
23,351 |
30,590 |
396,515 |
| Rajavelu Esther | CFO & CBO |
Nov 08 '24 |
Sale |
1.30 |
17,245 |
22,418 |
379,270 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):